Sanara MedTech (SMTI) – A Profitable 90%+ Gross Margin Surgical Products Business

Sanara is a profitable, growing, 90%+ gross margin small-cap med-tech company trading at 1/2 of peer group multiple. The surgical business is on a path toward 20% growth or roughly $125 million in revenue and around $25 million in EBITDA in 2026, representing a multiple today of 1.75x EV/Sales and 8.8x EV/EBITDA. Peer med-tech companies with similar growth and margin characteristics typically trade at 3- 6x sales and in the low-teens to high-teens on EBITDA. The shutdown of THP (discontinued operations) in late 2025, will make the financials much cleaner and easier for investors to see and model through 2026 and beyond. The setup is in place for a meaningful re-rating along with operational progress as the story becomes purely surgical and operating leverage continues to show through. https://sanaramedtech.com

In this discussion, Chris Plahm and I have a conversation with CEO Seth Yon and CFO Elizabeth Taylor. You can follow the ongoing discussion on Sanara MedTech on our community here.

You can listen/watch this business breakdowns on Spotify, Apple Podcast, and YouTube below:

_{Disclaimer: All content in this newsletter is for discussion, education, entertainment, and illustrative purposes only and SHOULD NOT be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on this newsletter and MicroCapClub.com. There are risks associated with investing in securities. Loss of principal is possible. Past performance is not a predictor of future investment performance. Ian Cassel and MicroCapClub.com are not responsible for investment actions taken by viewers. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing. Any past performance discussed on MicroCapClub.com is no guarantee of future results. Investing involves risk and possible loss of principal capital; please seek advice from a licensed professional. All views expressed are personal opinions as of the date of publication and are subject to change without the responsibility to update views. No guarantee is given regarding the accuracy of the information. FULL DISCLAIMER and TERMS OF USE}